HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed)

The summary for the HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed): The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites applications from investigators willing to participate with the NICHD + others for an observational clinical study of infants born to mothers who are exposed to prenatal opioids. The public health opioid epidemic has a significant effect on infants who were exposed prenatally to opioids. This funding opportunity announcement (FOA) is intended to support multi-site clinical research devoted to investigating the impact of prenatal opioid exposure on infant outcomes as well as neuroimaging in opioid exposed versus unexposed newborns. The objective of this program is to advance scientific research that facilitates knowledge and care for infants exposed in utero to opioids. This program benefits the public: infants and families with opioid exposure and their health care providers. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating sites develop a specific protocol across the sites and are organized to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and each consortium includes a mechanism for coordination, implementation and monitoring of the protocol across sites, quality control, database management, statistical analysis, and reporting. Public Law 115-141, the Consolidated Appropriations Act of 2018 (signed on March 23, 2018) includes a requirement that grantees from for-profit applicant organizations must provide a 50% match and/or in-kind contribution of all federally awarded dollars under the grant award (direct costs, as well as facilities and administrative costs) for research related to opioid addiction, development of opioid alternatives, pain management and addiction treatment.

Federal Grant Title:	HEAL Initiative: Antenatal Opioid Exposure Longitudinal Study Consortium (PL1 Clinical Trials Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HD-19-025
Type of Funding:	Grant
CFDA Numbers:	93.865
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 29th, 2019
Original Application Deadline:	March 29th, 2019
Posted Date:	December 10th, 2018
Creation Date:	December 10th, 2018
Archive Date:	May 4th, 2019
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	December 10th, 2018

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-19-025.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allo...; • National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 C...; • Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescen...; • Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed); • Biological Testing Facility (X01 Clinical Trial Not Allowed); • Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...; • Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...; • Reproductive Genetics and Epigenetics
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...